Serotonin 5HT2C Agonist Drugs with 5HT2A/2B Antagonist Activity

具有 5HT2A/2B 拮抗活性的血清素 5HT2C 激动剂药物

• 批准号: 8538587
• 负责人: Raymond G. Booth
• 金额: $ 33.1万
• 依托单位: NORTHEASTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-08 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8538587
• 关键词: Active Sites; Address; Adult; Affinity; Agonist; Amino Acids; Amphetamines; Animals; Behavior; Binding; Body Weight decreased; Brain; Cardiac; Cardiovascular Diseases; Cattle; Cells; Chemicals; Child; Data; Development; Diabetes Mellitus; Disease; Docking; Drug Evaluation; Eating; Electronics; Electrostatics; Evaluation; G-Protein-Coupled Receptors; Health; Homology Modeling; Human; In Vitro; Inhibitory Concentration 50; Inositol Phosphates; Knock-out; Lead; Ligands; Locomotion; Malignant Neoplasms; Maps; Membrane; Mental Depression; Mental disorders; Modeling; Molecular; Molecular Conformation; Molecular Mechanisms of Action; Molecular Models; Morbidity - disease rate; Mus; Mutagenesis; Mutate; Mutation; Obesity; Outcome; Overweight; Peripheral; Pharmaceutical Preparations; Pharmacotherapy; Phospholipase C; Point Mutation; Positioning Attribute; Psychotic Disorders; Pulmonary Hypertension; Quantitative Structure-Activity Relationship; Receptor Signaling; Recombinants; Relative (related person); Reporting; Research; Role; Serotonin; Structure; Study models; Testing; aged; analog; attenuation; base; cardiovascular disorder risk; chemical synthesis; computational chemistry; drug structure; drug testing; food consumption; in vivo; innovation; molecular modeling; molecular recognition; neurobehavioral; neuropsychiatry; pharmacophore; pre-clinical; preclinical evaluation; preclinical study; psychologic; receptor; receptor binding; rho; social; tetralin; three dimensional structure

DESCRIPTION (provided by applicant): There is compelling evidence that activation of brain serotonin 5HT2C G protein-coupled receptors (GPCRs) produces anti-obesity effects in humans, attenuation of psychomimetic activity, and other neuropsychiatric effects. Meanwhile, activation of brain 5HT2A GPCRs produces psychomimetic effects and activation of peripheral 5HT2B GPCRs produces cardiac valvulopathy and pulmonary hypertension. Currently, there is no 5HT2C receptor agonist reported that does not also activate 5HT2A and/or 5HT2B receptors. This research proposes to exploit a compound synthesized in our lab, (1R,3S)-(-)-trans-1-phenyl-3-dimethylamino-1,2,3,4- tetrahydronaphthalene (PAT), that is a full-efficacy agonist at human 5HT2C receptors, plus, it is an antagonist at 5HT2A and 5HT2B receptors. As a small (MW=250) lipophilic molecule, (-)-trans-PAT readily penetrates mouse brain after peripheral (IP) administration to inhibit food consumption, produce weight loss, and inhibit amphetamine-induced locomotion, neurobehavioral effects consistent with 5HT2C agonism and 5HT2A antagonism. This research proposes preclinical evaluation of (-)-trans-PAT as pharmacotherapy for obesity and neuropsychiatric disorders, and, synthesis of other PATs with potent and efficacious 5HT2C agonist activity; PATs with potent 5HT2A/5HT2B antagonism may be lead drugs for psychiatric or cardiovascular diseases. We also have identified a potent PAT-type 5HT2C inverse agonist useful especially to characterize molecular determinants involved in ligand-directed 5HT2C function. Targeted medicinal chemical syntheses will provide PAT type stereo-probes as test drugs for preclincial evaluation and to map molecular determinants for 5HT2C binding/activation for inferences of receptor 3D structure. Forty PATs already are available and 32 new analogs will help delineate the PAT- 5HT2C pharmacophore - the optimal PAT steric, lipophilic, and electronic chemical molecular features. In vitro binding/functional studies will continue to be conducted using clonal cells expressing recombinant human 5HT2A, 5HT2B, or 5HT2C receptors - preliminary results and PAT-5HT2C 3D QSAR and receptor homology models lead us to propose construction and expression of D3.32A, S3.36A, A5.46N, A5.46S, F5.47A, F5.48A, W6.48A, F6.51A, F6.52A, Y7.43A, & Y7.53A point-mutated 5HT2C receptors to validate hypothesized PAT- 5HT2C binding/function interactions. In an iterative fashion, pharmacological results and molecular models generate additional hypotheses to test involving additional PAT syntheses and 5HT2C point-mutations for receptor characterization and development of PAT-type 5HT2C agonist drug structures. Preclinical studies to evaluate PATs as pharmacotherapy for obesity, eating and other neuropsychiatric disorders, as well as, to determine in vivo molecular mechanisms of action, are conducted using wild-type vs. genetically modified mice with global disruption ("knock-out") of 5HT2C and 5HT2A receptor signaling. PUBLIC HEALTH RELEVANCE: About 65% of adults and 16% of children aged 6-19 years in the U.S. currently (2005) are overweight or obese. Obesity is associated with increased risk for cardiovascular disease; diabetes; certain forms of cancer, depression, and various other physical, psychological, and social morbidities. Current pharmacotherapy available for obesity is unsatisfactory. This research seeks to develop new drugs to treat obesity, as well as, certain neuropsychiatric disorders.

描述（由申请人提供）：有令人信服的证据表明，脑5 -羟色胺5HT2C G蛋白偶联受体（gpcr）的激活在人类中产生抗肥胖作用，衰减拟精神病活动和其他神经精神作用。同时，大脑5HT2A gpcr的激活产生精神模拟效应，外周5HT2B gpcr的激活产生心脏瓣膜病和肺动脉高压。目前，还没有5HT2C受体激动剂不激活5HT2A和/或5HT2B受体的报道。本研究拟利用本实验室合成的化合物(1R,3S)-(-)-反式-1-苯基-3-二甲氨基-1,2,3,4-四氢萘（PAT），作为人5HT2C受体的全效激动剂，同时也是5HT2A和5HT2B受体的拮抗剂。（-）-trans- pat是一种小的（MW=250）亲脂分子，外周（IP）给药后，(-)-trans- pat容易穿透小鼠大脑，抑制食物消耗，减轻体重，抑制安非他明诱导的运动，其神经行为作用与5HT2C激动作用和5HT2A拮抗作用一致。本研究提出了(-)-反式pat作为肥胖和神经精神疾病药物治疗的临床前评估，以及其他具有强效5HT2C激动剂活性的pat的合成；具有强效5HT2A/5HT2B拮抗剂的PATs可能是治疗精神或心血管疾病的主要药物。我们还发现了一种有效的pat型5HT2C逆激动剂，特别适用于表征与配体定向5HT2C功能相关的分子决定因素。靶向药物化学合成将提供PAT型立体探针作为临床前评估的测试药物，并绘制5HT2C结合/激活的分子决定因素，以推断受体3D结构。已有40种PAT可用，32种新的类似物将有助于描绘PAT- 5HT2C药效团-最佳的PAT立体，亲脂性和电子化学分子特征。体外结合/功能研究将继续使用表达重组人5HT2A、5HT2B或5HT2C受体的克隆细胞进行。初步结果和PAT-5HT2C 3D QSAR和受体同源性模型使我们提出构建和表达D3.32A、S3.36A、A5.46N、A5.46S、F5.47A、F5.48A、W6.48A、F6.51A、F6.52A、Y7.43A和Y7.53A点突变5HT2C受体，以验证假设的PAT-5HT2C结合/功能相互作用。以迭代的方式，药理学结果和分子模型产生额外的假设来测试，涉及额外的PAT合成和5HT2C点突变，用于受体表征和PAT型5HT2C激动剂药物结构的开发。临床前研究评估PATs作为肥胖、饮食和其他神经精神疾病的药物治疗，并确定其在体内的分子作用机制，研究人员使用5HT2C和5HT2A受体信号整体破坏（“敲除”）的野生型和转基因小鼠进行了研究。公共卫生相关性：目前（2005年）美国约65%的成年人和16%的6-19岁儿童超重或肥胖。肥胖与心血管疾病风险增加有关；糖尿病;某些形式的癌症、抑郁症和其他各种生理、心理和社会疾病。目前可用于肥胖的药物治疗并不令人满意。这项研究旨在开发治疗肥胖和某些神经精神疾病的新药。

项目成果

A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual action.

自闭症的一种新的潜在治疗途径：具有双重作用的 SSRI 的设计、合成和药效基团生成。

• DOI: 10.1016/j.bmcl.2011.09.046
• 发表时间: 2011
• 期刊: Bioorganic & medicinal chemistry letters
• 影响因子: 2.7
• 作者: Ghoneim,OlaM;Ibrahim,DiaaA;El-Deeb,IbrahimM;Lee,SoHa;Booth,RaymondG
• 通讯作者: Booth,RaymondG